Kineta Operating Margin 2014-2024 | KANT
Current and historical operating margin for Kineta (KANT) over the last 10 years. The current operating profit margin for Kineta as of June 30, 2024 is 0.00%.
| Kineta Operating Margin Historical Data |
| Date |
TTM Revenue |
TTM Operating Income |
Operating Margin |
| 2023-12-31 |
$0.01B |
$-0.02B |
-300.00% |
| 2023-06-30 |
$0.01B |
$-0.04B |
-760.00% |
| 2023-03-31 |
$0.00B |
$-0.04B |
-4200.00% |
| 2022-12-31 |
$0.00B |
$-0.04B |
-4100.00% |
| 2022-09-30 |
$0.00B |
$0.00B |
133.33% |
| 2022-06-30 |
$0.01B |
$-0.00B |
-40.00% |
| 2022-03-31 |
$0.01B |
$-0.01B |
-116.67% |
| 2021-12-31 |
$0.01B |
$-0.01B |
-110.00% |
| 2021-09-30 |
$0.01B |
$-0.07B |
-541.67% |
| 2021-06-30 |
$0.01B |
$-0.06B |
-469.23% |
| 2019-03-31 |
$0.01B |
$-0.07B |
-957.14% |
| 2018-09-30 |
$0.01B |
$-0.06B |
-1200.00% |
| 2018-06-30 |
$0.01B |
$-0.06B |
-916.67% |
| 2018-03-31 |
$0.01B |
$-0.06B |
-933.33% |
| 2017-12-31 |
$0.01B |
$-0.06B |
-1000.00% |
| 2017-09-30 |
$0.01B |
$-0.06B |
-700.00% |
| 2017-06-30 |
$0.01B |
$-0.05B |
-662.50% |
| 2017-03-31 |
$0.01B |
$-0.05B |
-562.50% |
| 2016-12-31 |
$0.01B |
$-0.04B |
-475.00% |
| 2016-09-30 |
$0.01B |
$-0.03B |
-680.00% |
| 2016-06-30 |
$0.00B |
$-0.03B |
-750.00% |
| 2016-03-31 |
$0.00B |
$-0.03B |
-700.00% |
| 2015-12-31 |
$0.00B |
$-0.03B |
-625.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.005B |
|
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
|
